BRPI0417491A - composção e métodos para modular a atividade do snc - Google Patents

composção e métodos para modular a atividade do snc

Info

Publication number
BRPI0417491A
BRPI0417491A BRPI0417491-7A BRPI0417491A BRPI0417491A BR PI0417491 A BRPI0417491 A BR PI0417491A BR PI0417491 A BRPI0417491 A BR PI0417491A BR PI0417491 A BRPI0417491 A BR PI0417491A
Authority
BR
Brazil
Prior art keywords
methods
compositions
present
composition
disorders
Prior art date
Application number
BRPI0417491-7A
Other languages
English (en)
Inventor
Lee L Rubin
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of BRPI0417491A publication Critical patent/BRPI0417491A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIçãO E MéTODOS PARA MODULAR A ATIVIDADE DO SNC A presente invenção diz respeito a métodos e composições para tratar depressão e outros distúrbios comportamentais e/ou emocionais do sistema nervoso central por administração de sinalizador de ouriço. Outros distúrbios receptíveis a tratamento pelo método em questão incluem distúrbios hiperativos com déficit de atenção, demência não-Alzheimer, e vários sintomas de perda de memória. A presente invenção diz respeito também a métodos e composições para melhorar a memória e/ou funções cognitivas, tanto em um paciente que sofre de doença que afeta estas funções como em um paciente que déficit de memória ou de função cognitiva não diagnosticada. Os métodos e composições da presente invenção estimulam a neurogênese e diferenciação, e melhoram a transmissão sináptica dos neurónios.
BRPI0417491-7A 2003-12-19 2004-12-15 composção e métodos para modular a atividade do snc BRPI0417491A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53120103P 2003-12-19 2003-12-19
PCT/US2004/042271 WO2005061002A2 (en) 2003-12-19 2004-12-15 Composition and methods for modulating cns activity

Publications (1)

Publication Number Publication Date
BRPI0417491A true BRPI0417491A (pt) 2007-05-22

Family

ID=34710209

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417491-7A BRPI0417491A (pt) 2003-12-19 2004-12-15 composção e métodos para modular a atividade do snc

Country Status (9)

Country Link
US (1) US20050203014A1 (pt)
EP (1) EP1694353A2 (pt)
JP (1) JP2007521333A (pt)
CN (1) CN1917897A (pt)
AU (1) AU2004305582A1 (pt)
BR (1) BRPI0417491A (pt)
CA (1) CA2547338A1 (pt)
MX (1) MXPA06006659A (pt)
WO (1) WO2005061002A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632679B2 (en) * 2002-07-16 2009-12-15 The Trustees Of Columbia University In The City Of New York Systems and methods for screening for modulators of neural differentiation
US7390659B2 (en) 2002-07-16 2008-06-24 The Trustees Of Columbia University In The City Of New York Methods for inducing differentiation of embryonic stem cells and uses thereof
US20040224302A1 (en) * 2002-07-16 2004-11-11 Thomas Jessel Systems and methods for screening for modulators of neural differentiation
WO2007028770A1 (en) * 2005-09-05 2007-03-15 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitors for neuroprotection in patients suffering from an advanced stage of a mental disease
JP2009521403A (ja) * 2005-11-14 2009-06-04 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Ｍｒｉによる神経発生の相関の画像法
WO2008127974A1 (en) * 2007-04-13 2008-10-23 The Trustees Of Columbia University In The City Of New York Stem cell-based culture system for drug development
US8969081B2 (en) * 2008-12-10 2015-03-03 The Trustees Of Columbia University In The City Of New York Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid
FR2966733B1 (fr) * 2010-10-29 2012-12-14 Centre Nat Rech Scient Nouvelles strategies therapeutiques impliquant la voie de signalisation hedgehog
CN104740633A (zh) * 2013-12-26 2015-07-01 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
JP6193176B2 (ja) * 2014-05-12 2017-09-06 ライオン株式会社 活力及び／又は集中力向上剤
CN111551729B (zh) * 2020-04-27 2021-02-09 浙江正熙生物技术股份有限公司 藻红蛋白免疫荧光探针制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610656B1 (en) * 1993-12-30 2003-08-26 President And Fellows Of Harvard College Method of promoting chondrocyte differentiation with hedgehog related polypeptides
US5789543A (en) * 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
US6165747A (en) * 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
US6261786B1 (en) * 1993-12-30 2001-07-17 Imperial Cancer Res. Technology Screening assays for hedgehog agonists and antagonists
US6384192B1 (en) * 1993-12-30 2002-05-07 President & Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins
US6027882A (en) * 1994-10-07 2000-02-22 The Regents Of The University Of California Patched genes and their use for diagnostics
US6429354B1 (en) * 1994-10-07 2002-08-06 The Board Of Trustees Of The Leland Stanford Junior University Patched genes and uses related thereto
EP1616942A3 (en) * 1994-10-07 2006-11-22 The Board Of Trustees Of The Leland Stanford Junior University Patched genes and their use
US7144997B2 (en) * 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
CA2352570A1 (en) * 1998-12-03 2000-06-22 Biogen, Inc. Methods and compositions for treating disorders involving excitotoxicity
EP1743903A2 (en) * 1998-12-03 2007-01-17 Curis, Inc. Methods and compositions for treating disorders involving excitotoxicity
EP1240184A2 (en) * 1999-12-21 2002-09-18 University Of Zurich "dispatched" polypeptides
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
AU2001259252A1 (en) * 2000-04-28 2001-11-12 Curis, Inc. Neuroprotective compositions
AU2002231206A1 (en) * 2000-12-21 2002-07-01 The Mclean Hospital Corporation Treatment of depression
US20060078499A1 (en) * 2003-12-01 2006-04-13 Rene Hen Use of hedgehog agonist to treat depression

Also Published As

Publication number Publication date
WO2005061002A3 (en) 2005-09-29
MXPA06006659A (es) 2006-08-31
WO2005061002A2 (en) 2005-07-07
CN1917897A (zh) 2007-02-21
JP2007521333A (ja) 2007-08-02
US20050203014A1 (en) 2005-09-15
CA2547338A1 (en) 2005-07-07
AU2004305582A1 (en) 2005-07-07
EP1694353A2 (en) 2006-08-30

Similar Documents

Publication Publication Date Title
Park et al. Physical exercise during exposure to 40-Hz light flicker improves cognitive functions in the 3xTg mouse model of Alzheimer’s disease
Manenti et al. M ild cognitive impairment in Parkinson's disease is improved by transcranial direct current stimulation combined with physical therapy
Boggio et al. Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression
Su et al. Intermittent theta burst transcranial magnetic stimulation for methamphetamine addiction: A randomized clinical trial
Gobrecht et al. Sustained GSK3 activity markedly facilitates nerve regeneration
Rossi et al. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo‐controlled study
Kreuzer et al. Mindfulness-and body-psychotherapy-based group treatment of chronic tinnitus: a randomized controlled pilot study
Guillaume et al. Improving decision‐making and cognitive impulse control in bulimia nervosa by rTMS: an ancillary randomized controlled study
Baydas et al. Learning and memory deficits in rats induced by chronic thinner exposure are reversed by melatonin
BR0313153A (pt) Derivado de quinuclidina, composição farmacêutica, uso de um derivado de quinuclidina, e, método de tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição de um corpo animal vivo
BRPI0417491A (pt) composção e métodos para modular a atividade do snc
Michiels Somatosensory tinnitus: recent developments in diagnosis and treatment
Yildiz et al. Cognitive outcomes of transcranial magnetic stimulation in treatment-resistant depression: a randomized controlled study
Stockbridge et al. Reversing the ruin: rehabilitation, recovery, and restoration after stroke
Sharifi-Fardshad et al. Modulation of drug craving in crystalline-heroin users by transcranial direct current stimulation of dorsolateral prefrontal cortex
de Azevedo et al. Treatment of tinnitus with acamprosate
Ikeda et al. Differential rostral projections of caudal brainstem neurons receiving trigeminal input after masseter inflammation
Bellingacci et al. Oligomeric alpha-synuclein causes early synaptic dysfunction of the corticostriatal pathway associated with non-motor symptoms
Saxena et al. Systematic review of the effectiveness of homoeopathy in the treatment of autism spectrum disorder
Martins et al. Enhancing nerve regeneration in infraorbital nerve injury rat model: effects of vitamin B complex and photobiomodulation
Al-Ayadhi et al. Effectiveness of Auditory Integration Therapy in Autism Spectrum Disorders--Prospective Study.
Konjusha et al. Auricular transcutaneous vagus nerve stimulation for alcohol use disorder: A chance to improve treatment?
Dakwar et al. New directions in medication-facilitated behavioral treatment for substance use disorders
Saito et al. A proposed molecular mechanism for physical analgesia in chronic pain
DE60137414D1 (de) Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.